TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cluster-randomized, Non-inferiority Open-label Trial of the Impact of Supplementation Regimen on Consumption of Prenatal Calcium and Iron/Folic Acid Supplements and Adherence to Related Recommendations
Brief Summary: The World Health Organization (WHO) now recommends prenatal calcium supplementation for prevention of preeclampsia in populations with inadequate dietary intake. This study seeks to compare the effect of two dosing strategies on the amount of supplement ingested by pregnant women and adherence to related recommendations.


Options:
A: Arm Label: Regimen A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Regimen A calcium and iron/folic acid | Arm Label: Regimen B; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Regimen B calcium and iron/folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen A calcium and iron/folic acid; Assigned to Arm(s): Regimen A | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen B calcium and iron/folic acid; Assigned to Arm(s): Regimen B
B: Arm Label: 10 mcg Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 10 mcg Vitamin D3 | Arm Label: 20 mcg Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 20 mcg Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 10 mcg Vitamin D3; Assigned to Arm(s): 10 mcg Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 20 mcg Vitamin D3; Assigned to Arm(s): 20 mcg Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: cholecalciferol-400 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Arm Label: cholecalciferol 2000 IU; Type: EXPERIMENTAL; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Arm Label: cholecalciferol 4000 IU; Type: EXPERIMENTAL; Interventions: Drug: cholecalciferol (vitamin D3), Drug: cholecalciferol | Intervention Type: DRUG; Name: cholecalciferol (vitamin D3); Assigned to Arm(s): cholecalciferol 2000 IU, cholecalciferol 4000 IU, cholecalciferol-400 IU | Intervention Type: DRUG; Name: cholecalciferol; Assigned to Arm(s): cholecalciferol 2000 IU, cholecalciferol 4000 IU, cholecalciferol-400 IU
D: Arm Label: Vitamin D treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 3 cholecalciferol, Dietary Supplement: Vitamin D3 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 3 cholecalciferol; Assigned to Arm(s): Vitamin D treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D treatment, placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)
Brief Summary: This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment).


Options:
A: Arm Label: polypill; Type: EXPERIMENTAL; Interventions: Drug: polypill | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Usual cardiovascular medications | Intervention Type: DRUG; Name: polypill; Assigned to Arm(s): polypill | Intervention Type: DRUG; Name: Usual cardiovascular medications; Assigned to Arm(s): Usual Care
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
C: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel, Drug: Aspirin | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel placebo, Drug: Aspirin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination therapy | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Monotherapy | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Combination therapy, Monotherapy
D: Arm Label: dabigatran etexilate 110 or 150 mg; Type: EXPERIMENTAL; Interventions: Drug: optional ASA as comedication, Drug: placebo to ASA, Drug: dabigatran etexilate | Arm Label: ASA 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo to optional ASA as comedication, Drug: placebo to dabigatran etexilate, Drug: ASA 100 mg | Intervention Type: DRUG; Name: optional ASA as comedication; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to ASA; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to optional ASA as comedication; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: placebo to dabigatran etexilate; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: ASA 100 mg; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multicenter, Open-Label, First-in-Human Phase 1/2 Study With Two Cohorts to Evaluate the Safety, Tolerability, and Efficacy of Various Doses of VC-01™ Combination Product in Subjects With Type 1 Diabetes Mellitus
Brief Summary: The purpose of this trial is to test if VC-01™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for two years. It will also test if VC-01 is an effective treatment for subjects with Type 1 Diabetes.


Options:
A: Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Website Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Website Intervention | Intervention Type: BEHAVIORAL; Name: Website Intervention; Assigned to Arm(s): Website Intervention
B: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Combination Product: VC-01™ Combination Product | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Combination Product: VC-01™ Combination Product | Intervention Type: COMBINATION_PRODUCT; Name: VC-01™ Combination Product; Assigned to Arm(s): Cohort 1, Cohort 2
D: Arm Label: Integrated Chronic Kidney Disease care; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Chronic Kidney Disease care | Arm Label: Conventional CKD care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional CKD care | Intervention Type: BEHAVIORAL; Name: Integrated Chronic Kidney Disease care; Assigned to Arm(s): Integrated Chronic Kidney Disease care | Intervention Type: BEHAVIORAL; Name: Conventional CKD care; Assigned to Arm(s): Conventional CKD care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)
Brief Summary: This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an outpatient (i.e., at home) and in the clinic.

Patients who successfully complete this study will be eligible to enroll into a 12 month treatment extension (CVT-301-004E) study.


Options:
A: Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Device: Libra Deep Brain Stimulation System | Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Device: Libra Deep Brain Stimulation System | Intervention Type: DEVICE; Name: Libra Deep Brain Stimulation System; Assigned to Arm(s): Group A | Intervention Type: DEVICE; Name: Libra Deep Brain Stimulation System; Assigned to Arm(s): Group B
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Other: ParkNet | Arm Label: II; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: ParkNet; Assigned to Arm(s): I | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): II
C: Arm Label: Dual Task Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dual Task Group | Arm Label: Single Task Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Single Task Group | Intervention Type: BEHAVIORAL; Name: Dual Task Group; Assigned to Arm(s): Dual Task Group | Intervention Type: BEHAVIORAL; Name: Single Task Group; Assigned to Arm(s): Single Task Group
D: Arm Label: CVT-301 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: CVT-301 Low Dose | Arm Label: CVT-301 High Dose; Type: EXPERIMENTAL; Interventions: Drug: CVT-301 High Dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CVT-301 Low Dose; Assigned to Arm(s): CVT-301 Low Dose | Intervention Type: DRUG; Name: CVT-301 High Dose; Assigned to Arm(s): CVT-301 High Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reaching High Risk Post-partum Women for Nutritional Assessment and Counseling Via a Telephone-based Coaching Program
Brief Summary: The purpose of the STAR-MAMA intervention is to develop a patient-tailored telephone-base counseling intervention for young Latino women who are at high risk of diabetes. The intervention will focus at the end of pregnancy and the 9 months post-partum period to improve education and behavioral counseling on nutrition and other related health topics .

The following hypotheses will be formally tested:

Compared with controls at 9 months post-partum:

1. Women in the STAR-Moms program will have improved self-reported behavioral outcomes for minutes of physical activity, lower fat diet, and breast-feeding duration (in weeks);
2. Women in the STAR-Moms program will have improved diabetes prevention knowledge;
3. Women in the STAR-Moms program will have increased diabetes-relevant screening rates.

Women in the STAR-MAMA will have lost more weight than women in the control group.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Care for Korean Americans | Intervention Type: BEHAVIORAL; Name: Diabetes Care for Korean Americans; Assigned to Arm(s): 1
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: dietary education | Intervention Type: BEHAVIORAL; Name: dietary education; Assigned to Arm(s): A
C: Arm Label: Lifestyle behavior intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle behavior interventon grop | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Placebo Comparator: Control group | Intervention Type: BEHAVIORAL; Name: Lifestyle behavior interventon grop; Assigned to Arm(s): Lifestyle behavior intervention group | Intervention Type: OTHER; Name: Placebo Comparator: Control group; Assigned to Arm(s): Control group
D: Arm Label: Life Style counseling (Star-Mama); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Life Style Counseling (Star-Mama) | Arm Label: Educational Resource Support; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Life Style Counseling (Star-Mama); Assigned to Arm(s): Life Style counseling (Star-Mama)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) Study
Brief Summary: This study aims to determine whether, compared with usual anesthetic care, an electroencephalography-guided anesthesia protocol is effective at preventing postoperative delirium and its downstream effects, and improving postoperative patient reported health-related quality of life.


Options:
A: Arm Label: desflurane and sevoflurane; Type: N/A; Interventions: Other: The intervention will be Mini-Mental Status Examination (MMSE) | Intervention Type: OTHER; Name: The intervention will be Mini-Mental Status Examination (MMSE); Assigned to Arm(s): desflurane and sevoflurane
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Bispectral index protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: End tidal anesthetic gas-guided | Intervention Type: BEHAVIORAL; Name: Bispectral index protocol; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: End tidal anesthetic gas-guided; Assigned to Arm(s): 2
C: N/A
D: Arm Label: EEG guided protocol; Type: EXPERIMENTAL; Interventions: Device: a pragmatic EEG-guided anesthetic protocol | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: a pragmatic EEG-guided anesthetic protocol; Assigned to Arm(s): EEG guided protocol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tools to Improve Parental Recognition of Developmental Deficits in Children
Brief Summary: In this study, we aim to improve child nutrition by increasing parents' awareness of their children's physical growth. We use a cluster-randomized trial design to evaluate two interventions that provide parents with regular information on their children's physical development and growth: 1) distribution of full-sized growth charts for measurement of child height within households; and 2) organization of community-based meetings, during which children's height and weight are measured by trained project staff.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition program developed using positive deviance approach | Arm Label: Comparison group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nutrition program developed using positive deviance approach; Assigned to Arm(s): Intervention group
B: Arm Label: Training Plus; Type: EXPERIMENTAL; Interventions: Behavioral: Training Plus | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: No Inputs then Community development and training | Arm Label: Training Only; Type: EXPERIMENTAL; Interventions: Behavioral: Training Only | Intervention Type: BEHAVIORAL; Name: Training Plus; Assigned to Arm(s): Training Plus | Intervention Type: BEHAVIORAL; Name: Training Only; Assigned to Arm(s): Training Only | Intervention Type: BEHAVIORAL; Name: No Inputs then Community development and training; Assigned to Arm(s): Control
C: Arm Label: Height measurement poster; Type: EXPERIMENTAL; Interventions: Behavioral: Height measurement poster | Arm Label: Community-based monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Community-based monitoring | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Height measurement poster; Assigned to Arm(s): Height measurement poster | Intervention Type: BEHAVIORAL; Name: Community-based monitoring; Assigned to Arm(s): Community-based monitoring
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Improving nutrition knowledge among mothers | Intervention Type: OTHER; Name: Improving nutrition knowledge among mothers; Assigned to Arm(s): intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving the Decision Making Process About Location of Care With the Frail Elderly and Their Caregivers
Brief Summary: One of the toughest decisions faced by the frail elderly in Canada is whether to stay at home or move to a care facility. It is certainly difficult to make this decision alone, but can be even harder if someone else makes it for you. Shared decision making is when, instead of making decisions for the patient, healthcare professionals share information about what the evidence says, and they talk about what's important with the patient, and then make the decision together. In the case of the frail elderly in home care services, there are many health care professionals involved, e.g. the doctor, nurse and social worker. In this case decisions should be shared by all the professionals involved with the elderly person along with his or her caregivers. Unfortunately, in this context, shared decision making rarely occurs.

We have designed a training program that teaches interprofessional teams how to share decisions with their frail elderly patients, and tested it in one Quebec City and one Edmonton home care team. This project tests the training program on a broader scale with 16 home care teams attached to community health centres across the province of Quebec, and will compare the results with what happens when no one has completed the training (usual care). Home care is a rapidly growing sector and this study will lay the foundations for a national strategy to ensure that no one has to make this difficult decision alone.


Options:
A: Arm Label: G_AH; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care group | Arm Label: G_SP; Type: OTHER; Interventions: Other: Phone-based care group | Arm Label: G_NOMHAD; Type: EXPERIMENTAL; Interventions: Device: Platform NOMHADchronic | Intervention Type: DEVICE; Name: Platform NOMHADchronic; Assigned to Arm(s): G_NOMHAD | Intervention Type: OTHER; Name: Phone-based care group; Assigned to Arm(s): G_SP | Intervention Type: OTHER; Name: Usual care group; Assigned to Arm(s): G_AH
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support, management, educational, counselling, follow-up | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Support, management, educational, counselling, follow-up; Assigned to Arm(s): Group A, Group B
C: Arm Label: Training; Type: EXPERIMENTAL; Interventions: Behavioral: Training | Arm Label: Usual care; Type: OTHER; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Training; Assigned to Arm(s): Training | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: Guided Care; Type: EXPERIMENTAL; Interventions: Behavioral: Guided Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Guided Care; Assigned to Arm(s): Guided Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-based Delivery of Integrated Family Planning/HIV Testing and Counseling Services in Uganda
Brief Summary: The purpose of this study is to evaluate the feasibility and acceptability of adding HIV testing and counseling (HTC) services to the family planning (FP) services provided by community health workers in Uganda.


Options:
A: Arm Label: Acyclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Generic acyclovir | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Generic acyclovir; Assigned to Arm(s): Acyclovir | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: FP and HTC services; Type: EXPERIMENTAL; Interventions: Other: FP and HTC services | Arm Label: FP services; Type: ACTIVE_COMPARATOR; Interventions: Other: FP services | Intervention Type: OTHER; Name: FP and HTC services; Assigned to Arm(s): FP and HTC services | Intervention Type: OTHER; Name: FP services; Assigned to Arm(s): FP services
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2
D: Arm Label: Integrated FP /PNC service delivery; Type: EXPERIMENTAL; Interventions: Procedure: Integrated FP/PNC service delivery | Arm Label: Non-integrated FP/PNC service delivery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Integrated FP/PNC service delivery; Assigned to Arm(s): Integrated FP /PNC service delivery

Answer: B